Hepatitis C and Hepatocellular Cancer: To Treat or Not to Treat
Authors:
Open Access
- 1 March 2021
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 17 (3) , 169-173
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular CarcinomaGastroenterology, 2019
- Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsGastroenterology, 2018
- HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinomaJournal of Hepatology, 2018
- Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral AgentsGastroenterology, 2017
- Impact of Sustained Virologic Response with Direct‐Acting Antiviral Treatment on Mortality in Patients with Advanced Liver DiseaseHepatology, 2017
- Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antiviralsJournal of Hepatology, 2017
- Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antiviralsJournal of Hepatology, 2016
- Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapyJournal of Hepatology, 2016
- Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2015
- Tumor Suppressors, Chromosomal Instability, and Hepatitis C Virus–Associated Liver CancerAnnual Review of Pathology: Mechanisms of Disease, 2009